Imbalance of the renin–angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?

Objective We evaluated the influence of the renin–angiotensin system (RAS) on intestinal inflammation and fibrosis. Design Cultured human colonic myofibroblast proliferation and collagen secretion were assessed following treatment with angiotensin (Ang) II and Ang (1–7), their receptor antagonists candesartan and A779, and the ACE inhibitor captopril. Circulating and intestinal RAS components were evaluated in patients with and without IBD. Disease outcomes in patients with IBD treated with ACE inhibitors and angiotensin receptor blockers (ARBs) were assessed in retrospective studies. Results Human colonic myofibroblast proliferation was reduced by Ang (1–7) in a dose-dependent manner (p<0.05). Ang II marginally but not significantly increased proliferation, an effect reversed by candesartan (p<0.001). Colonic myofibroblast collagen secretion was reduced by Ang (1–7) (p<0.05) and captopril (p<0.001), and was increased by Ang II (p<0.001). Patients with IBD had higher circulating renin (mean 25.4 vs 18.6 mIU/L, p=0.026) and ACE2:ACE ratio (mean 0.92 vs 0.69, p=0.015) than controls without IBD. RAS gene transcripts and peptides were identified in healthy and diseased bowels. Colonic mucosal Masson’s trichrome staining correlated with Ang II (r=0.346, p=0.010) and inversely with ACE2 activity (r=−0.373, p=0.006). Patients with IBD who required surgery (1/37 vs 12/75, p=0.034) and hospitalisation (0/34 vs 8/68, p=0.049) over 2 years were less often treated with ACE inhibitors and ARBs than patients not requiring surgery or hospitalisation. Conclusions The RAS mediates fibrosis in human cell cultures, is expressed in the intestine and perturbed in intestinal inflammation, and agents targeting this system are associated with improved disease outcomes.

[1]  G. Kaplan,et al.  Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression , 2018, Gut.

[2]  J. Fletcher,et al.  An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease , 2018, Alimentary pharmacology & therapeutics.

[3]  Michael Krawczak,et al.  Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases. , 2017, Gastroenterology.

[4]  S. Crowley,et al.  Immunologic Effects of the Renin-Angiotensin System. , 2017, Journal of the American Society of Nephrology : JASN.

[5]  Judy H. Cho,et al.  Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study , 2017, The Lancet.

[6]  A. Mikocka-Walus,et al.  Antidepressants in Inflammatory Bowel Disease: A Systematic Review , 2017, Inflammatory bowel diseases.

[7]  P. Gionchetti,et al.  European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly. , 2016, Journal of Crohn's & colitis.

[8]  M. Bissonnette,et al.  Activation of the Renin-Angiotensin System Promotes Colitis Development , 2016, Scientific Reports.

[9]  Y. Luqmani,et al.  Anti-Inflammatory Action of Angiotensin 1-7 in Experimental Colitis , 2016, PloS one.

[10]  P. Angus,et al.  Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study , 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[11]  C. Kvasnovsky,et al.  Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease , 2015, Scandinavian journal of gastroenterology.

[12]  J. Goldblum,et al.  Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem. , 2014, Inflammatory bowel diseases.

[13]  I. Grishina,et al.  MyD88 adaptor-like (Mal) functions in the epithelial barrier and contributes to intestinal integrity via protein kinase C , 2013, Mucosal Immunology.

[14]  L. Dauchet,et al.  Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[15]  Tsung-Teh Wu,et al.  Severe spruelike enteropathy associated with olmesartan. , 2012, Mayo Clinic proceedings.

[16]  P. Rosenstiel,et al.  ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation , 2012, Nature.

[17]  J. Savige,et al.  N-terminal pro-brain natriuretic peptide and angiotensin-converting enzyme-2 levels and their association with postoperative cardiac complications after emergency orthopedic surgery. , 2012, The American journal of cardiology.

[18]  P. Angus,et al.  Review article: the pathophysiological roles of the renin–angiotensin system in the gastrointestinal tract , 2012, Alimentary pharmacology & therapeutics.

[19]  D. Katz,et al.  Angiotensin-converting enzyme inhibitor-induced small-bowel angioedema: clinical and imaging findings in 20 patients. , 2011, AJR. American journal of roentgenology.

[20]  P. Lakatos,et al.  IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. , 2011, Journal of Crohn's & colitis.

[21]  J. Penninger,et al.  Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression , 2011, Regulatory Peptides.

[22]  L. P. de Sousa,et al.  Anti-Inflammatory Effects of the Activation of the Angiotensin-(1–7) Receptor, Mas, in Experimental Models of Arthritis , 2010, The Journal of Immunology.

[23]  M. Gooz.  ADAM-17: the enzyme that does it all , 2010, Critical reviews in biochemistry and molecular biology.

[24]  T Vrekoussis,et al.  Image analysis of breast cancer immunohistochemistry-stained sections using ImageJ: an RGB-based model. , 2009, Anticancer research.

[25]  L. Gakhar,et al.  Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[26]  J. Hugot,et al.  Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[27]  Hua Yang,et al.  Transanal delivery of angiotensin converting enzyme inhibitor prevents colonic fibrosis in a mouse colitis model: development of a unique mode of treatment. , 2008, Surgery.

[28]  P. Angus,et al.  Liver disease and the renin–angiotensin system: Recent discoveries and clinical implications , 2008, Journal of gastroenterology and hepatology.

[29]  L. Burrell,et al.  Angiotensin‐converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor , 2008, Experimental physiology.

[30]  C. Appleyard,et al.  An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis , 2008, Regulatory Peptides.

[31]  Y. Naito,et al.  Dextran sulfate sodium-induced acute colonic inflammation in angiotensin II type 1a receptor deficient mice , 2008, Inflammation Research.

[32]  J. Greenson,et al.  Reduced Severity of a Mouse Colitis Model with Angiotensin Converting Enzyme Inhibition , 2007, Digestive Diseases and Sciences.

[33]  S. Hernández-Díaz,et al.  Major congenital malformations after first-trimester exposure to ACE inhibitors. , 2006, The New England journal of medicine.

[34]  S. Umemura,et al.  Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice , 2005, Gut.

[35]  M. Pines,et al.  Prevention of Fibrosis in Experimental Colitis by Captopril: the Role of tgf-β1 , 2004, Inflammatory bowel diseases.

[36]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[37]  J. Bai.  Distribution of Brush-Border Membrane Peptidases Along the Rat Intestine , 1994, Pharmaceutical Research.

[38]  Qin Chen,et al.  Expression of renin-angiotensin system and extracellular matrix genes in cardiovascular cells and its regulation through AT1 receptor , 2004, Molecular and Cellular Biochemistry.

[39]  T. Resink,et al.  The renin-angiotensin system and extracellular matrix , 2004, The clinical investigator.

[40]  O. Schober,et al.  Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register , 2004, The clinical investigator.

[41]  C. Schaefer.  Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. , 2003, Birth defects research. Part A, Clinical and molecular teratology.

[42]  K. Clark,et al.  Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme , 2002, FEBS letters.

[43]  Nigel M. Hooper,et al.  A Human Homolog of Angiotensin-converting Enzyme , 2000, The Journal of Biological Chemistry.

[44]  S. Umemura,et al.  Expression of renin-angiotensin system and extracellular matrix genes in cardiovascular cells and its regulation through AT1 receptor. , 2000 .

[45]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[46]  F Breitenecker,et al.  Modified true-color computer-assisted image analysis versus subjective scoring of estrogen receptor expression in breast cancer: a comparison. , 1999, Anticancer research.

[47]  P. Rutgeerts,et al.  Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. , 1998, Gastroenterology.

[48]  I. Song,et al.  Rat intestinal angiotensin-converting enzyme: purification, properties, expression, and function. , 1992, The American journal of physiology.

[49]  R. Jaszewski,et al.  Increased colonic mucosal angiotensin I and II concentrations in Crohn's colitis. , 1990, Gastroenterology.

[50]  T. Resink,et al.  Modulation of extracellular matrix by angiotensin II: stimulated glycoconjugate synthesis and growth in vascular smooth muscle cells. , 1990, Journal of cardiovascular pharmacology.